Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Pr Garrattini is certainly right on most topics, but seems to have missed a very important issue: what happens after a Brexit?
A referendum is planned in the UK to define whether the UK (or is it England alone?) leaves the EU. IF this happens, what will become of the EMA in London. I do not see how a European institution can remain in a country that is no longer EU. Therefore the EMA will have to leave London to go elsewhere (Scotland, perhaps? I would favour the Netherlands, probably). What will this mean for ongoing drug evaluation processes? How much disruption will there be, with what consequences to patients, from drugs taking longer to reach the market, or from disruptions in the evaluation process? How many companies have set up offices in London or thereabouts to be closer to the EMA, that will leave the UK? How many EMA employees, and lobbyists, will have to relocate? What will be the economic consequences for UK labs and experts, and the effect on the influence of MHRA in EMA?
Has this been discussed publicly in the UK? This is an important matter for those who work in the medicines environment. It cannot simply be dismissed by stating Brexit will never happen. It might.